In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acerta Pharma BV

Division of AstraZeneca PLC
www.acerta-pharma.com

Latest From Acerta Pharma BV

Janssen's Imbruvica Leads CLL Market Expansion In Europe

Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.

 

Market Intelligence Cancer

AZ Pushes Further Ahead In PARP Race With Lynparza/Avastin Combo

The PAOLA-1 study has shown the benefit of Lynparza for ovarian cancer patients regardless of tumor mutation status which should firm up the drug's dominance in the PARP inhibitor space.

Cancer Clinical Trials

AZ’s Calquence Hits Endpoint In Second CLL Phase III Study

The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.

Clinical Trials Cancer

Positive CLL Data For AstraZeneca's BTK Inhibitor Prompts Early ASCEND Trial End

The Calquence Phase III ASCEND trial met its primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukemia and thus will stop early.

Clinical Trials Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Jurriaan Dekkers, CEO
    Edwin J Tucker, MD, COO
    Andrew Mortlock, PhD, CSO
  • Contact Info
  • Acerta Pharma BV
    Kloosterstraat 9
    Oss, 5349 AB
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register